TruInject Founder Gabrielle Rios Receives Nomination for Innovator of the Year

TruInject™ is pleased to announce the nomination of Innovator of the Year by the Orange County Business Journal.

Irvine, CA, August 09, 2016 --(PR.com)-- The Orange County Business Journal (OCBJ) has nominated Gabrielle Rios, founder of TruInject, for Innovator of the Year. The Orange County Business Journal's Innovator of the Year Awards honor, recognize and celebrate individuals and their organizations who are creating game-changing products and services, and demonstrate brilliance and leadership in innovation. Since founding the company 2013, Rios has focused on innovation by developing 'The TruInject Platform' which consists of an anatomical face model, a smart syringe and a comprehensive analytical software application with built-in 3D facial anatomy. "We are honored to receive the nomination along with so many innovative and diverse companies in our category. Our team at TruInject is made up of innovators who are working on next generation technologies our customers aren't even dreaming about yet. This nomination is really about them and what they contribute to our team every single day," Founder and CEO, Gabrielle Rios.

TruInject was founded to help healthcare professionals improve patient safety by creating the first injectable simulation system featuring 3D facial anatomy in the area of facial aesthetics. Last year, the FDA issued a warning concerning complications with cosmetic fillers about the possibility of rare, but serious, injuries that may occur due to unintentional injection of soft tissue fuller into blood vessels in the face. These occurrences could block the vessels and restrict blood supply to tissues, potentially causing problems such as vision impairment, blindness and stroke. "This device may help to single handedly prevent blindness in cases of ophthalmic artery occlusion," according to Dr. Sharon Stokes, Dermatologist. "It is critical that every healthcare provider that uses dermal fillers has a clear understanding of the anatomical features of the proposed treatment area in order to reduce the incidence of adverse outcomes," according to Dr. Steve Yoelin, Ophthalmologist and national trainer for injectables. "The TruInject platform will be the first and only device of its kind that has the unique ability to 'adapt' to new products, new procedures and new injection techniques. This device will help to ensure that adverse events will be minimized." The company is currently testing Microsoft's HoloLens augmented reality technology after being given early access by Microsoft.

The Awards will be held at Hotel Irvine on September 22, 2016.